USANA Health Sciences, Inc. (USNA) Cash Flow Statement

The OCF/NI ratio has swung from 0.77 in 2024Q2 to 2.78 in 2024Q3 and printed -1.09 in 2026Q2, which implies reported earnings carry very little information about near-term cash generation. Notably, the largest cash-positive quarters coincide with loss-making or low-earnings periods, suggesting accrual reversals and balance-sheet timing are doing more work than unit economics. This pattern is consistent with the prior income statement finding that non-operating items are materially distorting results, so valuation anchored on quarterly EPS is likely misleading.

Because the two strongest prints (2024Q3 at 13.6% margin and 2026Q2 at 9.0%) both leaned on positive working capital swings, the achievable mid-cycle FCF margin appears materially below the recent headline. Three of the ten quarters produced negative FCF, and all three occurred within a fourteen-month span. Given the flat-to-declining revenue baseline identified in the income statement work, sustaining even a low-single-digit FCF margin may require either repeatable working capital releases or genuine volume stabilization.

The heaviest draws were 2025Q4 (-$18.2M) and 2025Q3 (-$10.9M), which appear to be the primary mechanical drivers of the negative FCF during that stretch rather than operating deterioration alone. This profile is consistent with a distributor-prepayment model in which deferral balances, receivables and payables move in large, lumpy increments rather than smoothly. The implication is asymmetric: a reversal of the 2026Q2 release would compress free cash flow at precisely the moment operating profit has turned negative, so payables and receivables days warrant close monitoring.

Depreciation has roughly doubled from about $5.4M per quarter in early 2024 to around $10M per quarter by 2025Q4, so the widening earnings-to-cash gap appears to be a mechanical consequence of earlier capitalization now expensing rather than superior cash economics. Because the divergence is widest precisely in loss-making quarters, the cumulative 3x conversion ratio should not be read as evidence of earnings quality strength. As restructuring charges roll off and non-cash add-backs shrink proportionally, investors should expect this gap to narrow.

Roughly $49.8M of free cash flow has been generated since buybacks ceased in 2025Q2, and the suspension coincides with the FCF-negative stretch of 2025Q3–2025Q4, suggesting liquidity was prioritized during operational stress. There is no visible redeployment engine either — net acquisition outflow totaled just $48K in 2026Q1 — so retained cash is accruing without an identified use while peers such as Nu Skin distribute a 5.0% yield. Resumption of buybacks or initiation of a dividend would be the clearest read on management's confidence; continued silence may indicate caution about the durability of the direct-selling base.